7-acetyl-1-ethoxycarbonyl-1,2,3,4-tetrahydroquinoline | 1003021-60-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-acetyl-1-ethoxycarbonyl-1,2,3,4-tetrahydroquinoline
• 英文别名: ethyl 7-acetyl-3,4-dihydro-2H-quinoline-1-carboxylate
• CAS: 1003021-60-0
• 化学式: C₁₄H₁₇NO₃
• 分子量: 247.294
• InChiKey: YMIIIXQOXQKXET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-acetyl-1-ethoxycarbonyl-1,2,3,4-tetrahydroquinoline 生成 7-bromoacetyl-1-ethoxycarbonyl-1,2,3,4-tetrahydroquinoline*
  参考文献：
  名称：

  Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents

  摘要：

  该发明提供了以下公式的化合物：或其药学上可接受的盐，其中A是C1-6烷基或—NR1—；Z是C(═L)R2，或SO2R3；U是CH或N；W和Y分别选择自—CH2—，O，S和—N—R1；m为1、2或3；q和r独立地为0、1或2；X独立地选择自卤素，C1-4烷基，卤代C1-4烷基，羟基，C1-4烷氧基，卤代C1-4烷氧基或类似物；n为1或2；L为氧或硫；R1为氢或C1-4烷基；R2为羟基，C1-6烷基，卤代C1-6烷基，C1-6烷氧基，卤代C1-6烷氧基，C3-7环烷氧基，C1-4烷基(C3-7环烷氧基)，—NR4R5或类似物；R3为C1-6烷基或卤代C1-6烷基；R4和R5独立地选择自氢，C1-6烷基和卤代C1-6烷基。该发明还提供了一种药物组合物，用于治疗前列腺素作为病原体参与的医疗状况。

  公开号：

  US06303628B1

文献信息

• Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents and as COX-2 inhibitors
  申请人：PFIZER INC.

  公开号：EP1065204A1

  公开（公告）日：2001-01-03

  This invention provides a compound of the following formula: or the pharmaceutically acceptable salts thereof wherein A is C 1-6alkylene or -NR1-; Z is C(=L)R2, or SO2R3; U is CH or N; W and Y are independently selected from - CH2-, O, S and -N-R1; m is 1, 2 or 3; q and r are independently 0, 1 or 2; X is independently selected from halogen, C 1-4alkyl, halo-substituted C 1-4 alkyl, hydroxy, C 1-4alkoxy, halo-substituted C 1-4 alkoxy or the like; n is 1 or 2; L is oxygen or sulfur; R1 is hydrogen or C 1-4 alkyl; R2 is hydroxy, C1-6alkyl, halo-substituted C 1-6 alkyl, C 1-6 alkoxy, halo-substitutued C 1-6 alkoxy, C 3-7 cycloalkoxy, C 1-4 alkyl(C 3-7 cycloalkoxy), -NR4R5 or the like; R3 is C 1-6 alkyl or halo-substituted C 1-6 alkyl; and R4 and R5 are independently selected from hydrogen, C 1-6alkyl and halo-substituted C 1-6alkyl. This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.

  本发明提供了下式化合物： 或其药学上可接受的盐 其中A为C 1-6烷基或-NR1-；Z为C(＝L)R2或SO2R3；U为CH或N；W和Y独立地选自-CH2-、O、S和-N-R1；m为1、2或3；q和r独立地为0、1或2；X独立地选自卤素、C 1-4烷基、卤代C 1-4烷基、羟基、C 1-4烷氧基、卤代C 1-4烷氧基或类似物；n 是 1 或 2；L 是氧或硫；R1 是氢或 C 1-4 烷基；R2 是羟基、C1-6 烷基、卤代 C 1-6 烷基、C 1-6 烷氧基、卤代 C 1-6 烷氧基、C 3-7 环烷氧基、C 1-4 烷基（C 3-7 环烷氧基）、-NR4R5 或类似物；R3 是 C 1-6 烷基或卤代 C 1-6 烷基；以及 R4 和 R5 独立选自氢、C 1-6 烷基和卤代 C 1-6 烷基。 本发明还提供了一种药物组合物，可用于治疗前列腺素被认为是病原体的病症。
• US6303628B1
  申请人：——

  公开号：US6303628B1

  公开（公告）日：2001-10-16
• Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents
  申请人：Pfizer Inc

  公开号：US06303628B1

  公开（公告）日：2001-10-16

  This invention provides a compound of the following formula: or the pharmaceutically acceptable salts thereof wherein A is C 1-6 alkylene or —NR1—; Z is C(═L)R2, or SO2R3; U is CH or N; W and Y are independently selected from —CH2—, O, S and —N—R1; m is 1, 2 or 3; q and r are independently 0, 1 or 2; X is independently selected from halogen, C1-4 alkyl, halo-substituted C1-4 alkyl, hydroxy, C1-4 alkoxy, halo-substituted C1-4 alkoxy or the like; n is 1 or 2; L is oxygen or sulfur; R1 is hydrogen or C1-4 alkyl; R2 is hydroxy, C1-6alkyl, halo-substituted C1-6 alkyl, C1-6 alkoxy, halo-substituted C1-6 alkoxy, C3-7 cycloalkoxy, C1-4 alkyl(C3-7 cycloalkoxy), —NR4R5 or the like; R3 is C1-6 alkyl or halo-substituted C1-6 alkyl; and R4 and R5 are independently selected from hydrogen, C1-6 alkyl and halo-substituted C1-6alkyl. This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.

  该发明提供了以下公式的化合物：或其药学上可接受的盐，其中A是C1-6烷基或—NR1—；Z是C(═L)R2，或SO2R3；U是CH或N；W和Y分别选择自—CH2—，O，S和—N—R1；m为1、2或3；q和r独立地为0、1或2；X独立地选择自卤素，C1-4烷基，卤代C1-4烷基，羟基，C1-4烷氧基，卤代C1-4烷氧基或类似物；n为1或2；L为氧或硫；R1为氢或C1-4烷基；R2为羟基，C1-6烷基，卤代C1-6烷基，C1-6烷氧基，卤代C1-6烷氧基，C3-7环烷氧基，C1-4烷基(C3-7环烷氧基)，—NR4R5或类似物；R3为C1-6烷基或卤代C1-6烷基；R4和R5独立地选择自氢，C1-6烷基和卤代C1-6烷基。该发明还提供了一种药物组合物，用于治疗前列腺素作为病原体参与的医疗状况。